Trial Profile
A study evaluating safety, pharmacokinetics and outcomes of PAR-101 in patients with Clostridium difficile-associated diarrhoea.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections; Diarrhoea
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.